Welcome to the latest issue of Blockbuster Biologics Review, which covers the status and developments of post-grant challenges and patent litigations implicating blockbuster biologics and legislative proposals related to biosimilars in Q1 2024. We will continue to monitor developments in these post-grant challenges and litigations and provide you with regular updates.
Please see full publication below for more information.
